Citations

Showing 10 of 108152 citations.

Surgical Management of Irreparable Rotator Cuff Tears
Burnier, Marion , Elhassan, Bassem T. , Sánchez‐Sotelo, Joaquín , Sanchez-Sotelo, J.

Mayo Clinic

Journal of Bone and Joint Surgery | September 12, 2019 | Volume: 101 | Issue: 17 | Pages: 1603-1612

10.2106/jbjs.18.01392 | PMID 31483405 Get It

➤ The term functionally irreparable rotator cuff tear (FIRCT) is intended to capture patients who would experience failure of an attempted primary rotator cuff repair because of the extent of cuff muscle and tendon damage and other patient-related factors. ➤ Debridement, biceps tenodesis, and/or partial repair of the torn rotator cuff may reduce pain and improve function for selected patients with a FIRCT. ➤ Static soft-tissue restraints to abnormal glenohumeral head translation, such as implantation of an absorbable balloon in the subacromial space or superior capsular reconstruction (SCR), appear to reduce pain and improve function, although some have reported a relatively high structural failure rate with SCR. ➤ When improvement of strength is the primary goal of treatment, tendon transfers provide a viable treatment alternative; most tendon transfers for management of a FIRCT are currently performed with arthroscopically assisted techniques. ➤ Transfer of the lower portion of the trapezius has emerged as a successful alternative to transfer of the latissimus dorsi, whereas transfer of the latissimus dorsi to the lesser tuberosity is being explored as an alternative to transfer of the pectoralis major for functionally irreparable subscapularis tears.
Long-Term Survivorship of Total Hip Arthroplasty with Highly Cross-Linked Polyethylene for Osteonecrosis
Hart, Adam , Janz, Viktor , Trousdale, Robert T. , Sierra, Rafael J. , Berry, Daniel J. , Abdel, Matthew P. , Abdel, Matthew P , Sierra, Rafael J , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | September 12, 2019 | Volume: 101 | Issue: 17 | Pages: 1563-1568

10.2106/jbjs.18.01218 | PMID 31483399 Get It

Background: Osteonecrosis of the hip is the underlying etiology for 3% to 12% of total hip arthroplasties (THAs). Compared with patients who undergo THA because of osteoarthritis, those who do so because of osteonecrosis typically are younger, have a greater number of underlying diagnoses, and have inferior clinical outcomes and implant survivorship. The purpose of this study was to compare the long-term implant survivorship (median follow-up, 10 years), functional outcomes, and radiographic results of contemporary THAs with a highly cross-linked polyethylene (HXLPE) liner between patients with osteonecrosis and those with osteoarthritis. Methods: All patients who underwent primary THA with an HXLPE liner from 1999 to 2007 were identified from our institutional total joint registry. Patients with a primary diagnosis of osteonecrosis were matched 1:1, on the basis of age, sex, and body mass index (BMI), to patients with a diagnosis of osteoarthritis. This resulted in 461 hips in 413 patients with osteonecrosis matched to 461 hips in 427 patients with osteoarthritis (mean age, 59 years; 47% female; and mean BMI, 29 kg/m 2 ). Long-term implant survivorship, patient-reported outcomes, and radiographic findings were compared. In addition, a subgroup analysis of the osteonecrosis group was performed to see whether certain underlying etiologies portended poor outcomes. The median follow-up was 10 years. Results: The 15-year cumulative rates of revision were 6.6% and 4.5% in the osteonecrosis and osteoarthritis groups, respectively (hazard ratio [HR] = 1.8, p = 0.09). The 15-year cumulative rates of any reoperation were 10.5% and 6.4% in the osteonecrosis and osteoarthritis groups, respectively (HR = 2.2, p = 0.008). There were no radiographic signs of component loosening or osteolysis in the entire cohort. Despite a lower median preoperative Harris hip score (HHS) for patients with osteonecrosis, both groups had marked improvements in their scores, which were similar at all time points after surgery. The cumulative rate of reoperations at 15 years was 0% for hips with radiation-induced osteonecrosis, 6.3% for those with alcohol-induced osteonecrosis, 9.0% for those with posttraumatic osteonecrosis, 12.1% for those with steroid-induced osteonecrosis, and 25% for those with idiopathic osteonecrosis. Conclusions: Contemporary THA with an HXLPE liner offers excellent long-term implant survivorship and functional outcomes for patients with osteonecrosis; however, the risk of a reoperation is higher when compared with patients with osteoarthritis. Level of Evidence: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.
Esophageal Leukoplakia
Hernandez, Patricia V. , Snyder, Diana L. , Wang, Kenneth K. , Katzka, David A. , Horsley‐Silva, Jennifer L. , Snyder, Diana, Kahn, Allon , Horsley-Silva, Jennifer L

Mayo Clinic

ACG Case Reports Journal | September 12, 2019 | Volume: 6 | Issue: 9 | Pages: e00213

10.14309/crj.0000000000000213 | PMID 31750380 Get It

Factors That Affect Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Pancreatitis: A Systematic Review, Meta-Analysis, and Meta-Regression
Kurdi, Bara El , Babar, Sumbal, Iskandarani, Mahmoud El , Bataineh, Adam, Lerch, Markus M. , Young, Mark , Singh, Vijay , Singh, Vijay P, Singh, Vijay P

Mayo Clinic

Clinical and Translational Gastroenterology | September 12, 2019 | Volume: 10 | Issue: 9 | Pages: e00072

10.14309/ctg.0000000000000072 | PMID 31517648 Get It

OBJECTIVES: Small intestinal bacterial overgrowth (SIBO) can complicate chronic pancreatitis (CP) and interfere with management. Its predisposing factors in CP and treatment response are unknown. In this review, we evaluated factors affecting disease burden. METHODS: A computerized search of PubMed and EMBASE databases from inception through May 2019 was done for studies correlating SIBO with CP. Studies were screened, and relevant data were extracted and analyzed. Pooled prevalence, odds ratio (OR), and meta-regression were performed using the random effects model as classically described by Borenstein et al. (2009). SIBO's relation to diabetes mellitus (DM), pancreatic exocrine insufficiency (PEI), narcotic use, and proton-pump inhibitor use was investigated. Treatment response was pooled across studies. P value < 0.05 was considered significant. RESULTS: In 13 studies containing 518 patients with CP, SIBO prevalence was 38.6% (95% confidence interval [CI] 25.5–53.5). OR for SIBO in CP vs controls was 5.58 (95% CI 2.26–13.75). Meta-regression showed that PEI and the diagnostic test used were able to explain 54% and 43% of the variance in SIBO prevalence across studies, respectively. DM and PEI were associated with increased SIBO in CP with OR (2.1, 95% CI 1.2–3.5) and OR (2.5, 95% CI 1.3–4.8), respectively. Symptomatic improvement was reported in 76% of patients after SIBO treatment. DISCUSSION: SIBO complicates 38% of CP with OR of 5.58 indicating a predisposition for this condition. PEI correlates with SIBO in CP and might play a role in pathophysiology. DM and PEI are associated with increased SIBO in CP. Treatment of SIBO may lead to symptomatic improvement.
Online Health Information Seeking Among US Adults: Measuring Progress Toward a Healthy People 2020 Objective
Rutten, Lila J. Finney , Blake, Kelly D. , Greenberg, Alexandra J. , Allen, Summer V. , Finney Rutten, Lila J , Moser, Richard P. , Hesse, Bradford W.

Mayo Clinic

Public Health Reports® | September 12, 2019 | Volume: 134 | Issue: 6 | Pages: 617-625

10.1177/0033354919874074 | PMID 31513756 Get It

Objective: During the past decade, the availability of health information online has increased dramatically. We assessed progress toward the Healthy People 2020 (HP2020) health communication and health information technology objective of increasing the proportion of health information seekers who easily access health information online. Methods: We used data from 4 administrations of the Health Information National Trends Survey (HINTS 2008-2017) (N = 18 103). We conducted multivariable logistic regression analysis to evaluate trends over time in experiences with accessing health information and to examine differences by sociodemographic variables (sex, age, race/ethnicity, education, income, metropolitan status) separately for those who used the internet (vs other information sources) during their most recent search for health information. Results: Among US adults who looked for health information and used the internet for their most recent search, the percentage who reported accessing health information without frustration was stable during the study period (from 37.2% in 2008 to 38.5% in 2017). Accessing information online without frustration was significantly and independently associated with age 35-49 (vs age 18-34) (odds ratio [OR] = 1.34; 95% confidence interval [CI], 1.03 -1.73), non-Hispanic black (vs non-Hispanic white) race/ethnicity (OR = 2.15; 95% CI, 1.55-2.97), and annual household income <$20 000 (vs >$75 000) (OR = 0.66; 95% CI, 0.47-0.93). The percentage of adults who used an information source other than the internet and reported accessing health information online without frustration ranged from 31.3% in 2008 to 42.7% in 2017. Survey year 2017 (vs 2008) (OR = 1.61; 95% CI, 1.09-2.35) and high school graduate education (vs college graduate) (OR = 0.69; 95% CI, 0.49-0.97) were significantly and independently associated with accessing health information without frustration from sources other than the internet. Conclusions: The percentage of online health information seekers reporting easily accessing health information did not meet the HP2020 objective. Continued efforts are needed to enable easy access to online health information among diverse populations.
Hospital Partnerships in Population Health Initiatives
Park, Sinyoung , Apatu, Emma , Spaulding, Aaron , Spaulding, Aaron C. , Spaulding, Aaron , Hamadi, Hanadi

Mayo Clinic

Population Health Management | September 12, 2019 | Volume: 23 | Issue: 3 | Pages: 226-233

10.1089/pop.2019.0074 | PMID 31513480 Get It

Hospitals are expected to fulfill a role in the communities they serve by improving the health of the population in the community as mandated in the Affordable Care Act. One way hospitals achieve this is to create partnerships with diverse organizations, such as local public health departments, state/federal agencies, and other health care organizations. The aim of this study is to examine characteristics of hospitals that developed partnerships based on improving population health. This study utilized the 2015 Population Health Survey, American Hospital Association Database, and Dartmouth Atlas of Health Care. Hospital characteristics included size, ownership status, part of a system, teaching status location, Medicare percentage, Medicaid percentage, average stay length, and inpatient days per 1000 persons. Level of partnership was measured by the hospital's current working relationship with other hospitals/health care systems or local/state/other agencies. Univariate, bivariate, and multivariate regression analyses were used to analyze the relationship between hospital partnerships and organizational characteristics. Hospitals with strong relationships tend to be larger and not-for-profit hospitals, hospitals with system members and located in urban areas, and teaching-affiliated hospitals. This study also found hospital characteristics were related to hospitals' partnerships. Hospitals within health care systems and with high inpatient volume were more likely to report relationships that were stronger. This study provides a systematic and updated look at hospitals' partnership when looking at commitment to population health improvement and contributes to the literature by informing about the greater need to support rural and smaller hospitals with population health outreach activities.
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
Spratt, Daniel E. , Alshalalfa, Mohammed , Fishbane, Nick , Weiner, Adam B. , Mehra, Rohit , Mahal, Brandon A. , Lehrer, Jonathan , Zhao, Shuang G. , Speers, Corey , Morgan, Todd M. , Dicker, Adam P. , Freedland, Stephen J. , Karnes, R. Jeffery, Weinmann, Sheila , Ross, Ashley E. , Nguyen, Paul L. , Feng, Felix Y. , Chinnaiyan, Arul M., Schaeffer, Edward M. , Speers, Corey , Davicioni, Elai , Den, Robert B , Spratt, Daniel E , Morgan, Todd M , Dicker, Adam P , Liu, Yang , Zhao, Shuang G , Karnes, R. Jeffrey , Davicioni, Elai , Den, Robert B. , Lotan, Tamara Levin

Mayo Clinic

Clinical Cancer Research | September 12, 2019 | Volume: 25 | Issue: 22 | Pages: 6721-6730

10.1158/1078-0432.ccr-19-1587 | PMID 31515456 Get It

Abstract Purpose: The heterogeneity of androgen receptor (AR)-activity (AR-A) is well-characterized in heavily treated metastatic castration-resistant prostate cancer (mCRPC). However, the diversity and clinical implications of AR-A in treatment-naïve primary prostate cancer is largely unknown. We sought to characterize AR-A in localized prostate cancer and understand its molecular and clinical implications. Experimental Design: Genome-wide expression profiles from prostatectomy or biopsy samples from 19,470 patients were used, all with independent pathology review. This was comprised of prospective discovery (n = 5,239) and validation (n = 12,728) cohorts, six retrospective institutional cohorts with long-term clinical outcomes data (n = 1,170), and The Cancer Genome Atlas (n = 333). Results: A low AR-active subclass was identified, which comprised 9%–11% of each cohort, and was characterized by increased immune signaling, neuroendocrine expression, and decreased DNA repair. These tumors were predominantly ERG and basal subtype. Low AR-active tumors had significantly more rapid development of recurrence or metastatic disease across cohorts, which was maintained on multivariable analysis [HR, 2.61; 95% confidence interval (CI), 1.22–5.60; P = 0.014]. Low AR-active tumors were predicted to be more sensitive to PARP inhibition, platinum chemotherapy, and radiotherapy, and less sensitive to docetaxel and androgen-deprivation therapy. This was validated clinically, in that low AR-active tumors were less sensitive to androgen-deprivation therapy (OR, 0.41; 95% CI, 0.21–0.80; P = 0.008). Conclusions: Leveraging large-scale transcriptomic data allowed the identification of an aggressive subtype of treatment-naïve primary prostate cancer that harbors molecular features more analogous to mCRPC. This suggests that a preexisting subgroup of patients may have tumors that are predisposed to fail multiple current standard-of-care therapies and warrant dedicated therapeutic investigation.
Progesterone and Breast Cancer
Trabert, Britton , Kannan, Nagarajan , Stanczyk, Frank Z. , Trabert, B , Kannan, Nagarajan , Sherman, Mark E.

Mayo Clinic

Endocrine Reviews | September 12, 2019 | Volume: 41 | Issue: 2 | Pages: 320-344

10.1210/endrev/bnz001 | PMID 31512725 Get It

AbstractSynthetic progestogens (progestins) have been linked to increased breast cancer risk; however, the role of endogenous progesterone in breast physiology and carcinogenesis is less clearly defined. Mechanistic studies using cell culture, tissue culture, and preclinical models implicate progesterone in breast carcinogenesis. In contrast, limited epidemiologic data generally do not show an association of circulating progesterone levels with risk, and it is unclear whether this reflects methodologic limitations or a truly null relationship. Challenges related to defining the role of progesterone in breast physiology and neoplasia include: complex interactions with estrogens and other hormones (eg, androgens, prolactin, etc.), accounting for timing of blood collections for hormone measurements among cycling women, and limitations of assays to measure progesterone metabolites in blood and progesterone receptor isotypes (PRs) in tissues. Separating the individual effects of estrogens and progesterone is further complicated by the partial dependence of PR transcription on estrogen receptor (ER)α-mediated transcriptional events; indeed, interpreting the integrated interaction of the hormones may be more essential than isolating independent effects. Further, many of the actions of both estrogens and progesterone, particularly in “normal” breast tissues, are driven by paracrine mechanisms in which ligand binding to receptor-positive cells evokes secretion of factors that influence cell division of neighboring receptor-negative cells. Accordingly, blood and tissue levels may differ, and the latter are challenging to measure. Given conflicting data related to the potential role of progesterone in breast cancer etiology and interest in blocking progesterone action to prevent or treat breast cancer, we provide a review of the evidence that links progesterone to breast cancer risk and suggest future directions for filling current gaps in our knowledge.
Adverse drug reactions due to oral antibiotics prescribed in the community setting – England
Baddour, Larry M. , Dayer, Mark , Thornhill, Martin H. , Dayer, Mark J , Baddour, Larry , Thornhill, M H

Mayo Clinic

Infectious Diseases | September 12, 2019 | Volume: 51 | Issue: 11-12 | Pages: 866-869

10.1080/23744235.2019.1663918 | PMID 31512540 Get It

Faculty Opinions recommendation of Reimagining the research-practice relationship: policy recommendations for informatics-enabled evidence-generation across the US health system.
Liu, Hongfang

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | September 12, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.734909188.793564852 Get It